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ABSTRACT
Introduction: We investigated the impact of
reduced renal function on 24-h glucose
variability in Japanese patients with type 2
diabetes mellitus (T2DM) treated with
luseogliflozin.
Methods: In this double-blind,
placebo-controlled, crossover study, 37
Japanese patients with T2DM [glycated
hemoglobin (HbA1c) 7.0–10.0%] and
estimated glomerular filtration rate (eGFR)
C45 mL/min/1.73 m2 were randomized into
two groups in which patients first received
luseogliflozin then placebo, or vice versa, for
7 days each. Twenty-four-hour glucose
variability was measured on day 7 in each
period and was compared among patients
divided into three groups according to their
baseline eGFR (mL/min/1.73 m2): normal (C90;
n = 13; normal group), normal-to-mildly
reduced renal function (C75 to \90; n = 12;
normal–mild group), and mild-to-moderately
reduced renal function (\75; n = 9;
mild–moderate group).
Results: The mean [95% confidence interval
(CI)] placebo-subtracted 24-h cumulative
urinary glucose excretion (g) was 82.1 (72.7,
91.5), 82.5 (73.4, 91.5), and 62.2 (51.2, 73.3);
the placebo-subtracted 24-h mean glucose
concentration (mg/dL) was -24.39 (-32.53,
-16.26), -28.28 (-39.35, -17.22), and -11.53
(-23.93, 0.86); and the placebo-subtracted peak
postprandial glucose (mg/dL) was -26.9 (-46.9,
-6.9), -38.1 (-59.6, -16.6), and 1.5 (-25.5,
28.4) in the normal, normal–mild, and
mild–moderate groups, respectively. The mean
lowest glucose concentrations (placebo vs.
luseogliflozin, mg/dL) decreased to similar
levels in the normal (115.4 vs. 93.4),
normal–mild (121.0 vs. 97.9), and
mild–moderate (104.0 vs. 91.1) groups.
Conclusion: This post hoc subanalysis revealed
that although mild-to-moderately reduced renal
function attenuated the glucose-lowering
effects of luseogliflozin on peak postprandial
Electronic supplementary material The online
version of this article (doi:10.1007/s12325-016-0291-z)
contains supplementary material, which is available to
authorized users.
H. Jinnouchi
Jinnouchi Hospital, Kumamoto, Japan
K. Nozaki  H. Watase  H. Omiya  S. Sakai (&) 
Y. Samukawa
Taisho Pharmaceutical Co., Ltd, Tokyo, Japan
e-mail: so-sakai@so.taisho.co.jp
Adv Ther (2016) 33:460–479
DOI 10.1007/s12325-016-0291-z
glucose, it did not attenuate the effects of
luseogliflozin on fasting glucose. These findings
may explain the smaller increase in urinary
glucose excretion in these patients relative to
patients with normal renal function or
normal-to-moderately reduced renal function.
Further studies may be needed to examine these
findings in large populations of patients with
T2DM and reduced renal function.
Trial registration: JapicCTI-142548.
Funding: Taisho Pharmaceutical Co., Ltd.
Keywords: Continuous glucose monitoring;
Endocrinology; Estimated glomerular filtration
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function; SGLT2 inhibitor; Type 2 diabetes
mellitus
INTRODUCTION
Sodium–glucose cotransporter 2 (SGLT2)
inhibitors are newly approved drugs that
ameliorate hyperglycemia without increasing
the risk of hypoglycemia or body weight gain
compared with other glucose-lowering drugs
[1–3]. Accordingly, they are included as one of
the treatment options for combination therapy
of type 2 diabetes mellitus (T2DM) in the
current American Diabetes Association/
European Association for the Study of Diabetes
treatment recommendations [4].
Because the amount of glucose filtered
through the glomerulus and urinary glucose
excretion (UGE) are correlated with renal
function [5], it is important to investigate the
relationship between renal function/renal
impairment and the efficacy of SGLT2
inhibitors. Indeed, it has been reported that
the pharmacodynamics of SGLT2 inhibitors in
diabetic subjects with renal impairment are
consistent with the observation of reduced
efficacy in these patients [6], and that some
SGLT2 inhibitors are contraindicated in patients
with chronic kidney disease, or their daily dose
might need to be reduced [6].
Luseogliflozin is a highly selective and
potent SGLT2 inhibitor [7, 8] approved for use
as monotherapy or in combination with other
antidiabetic drugs based on the results of the
clinical trial program [9–11]. In a
pharmacokinetic/pharmacodynamic study
involving Japanese patients with T2DM, a
single dose of luseogliflozin significantly
increased 24-h UGE and significantly
decreased fasting blood glucose and 2-h
postprandial plasma glucose in patients with
normal renal function, mildly reduced renal
function, or moderately reduced renal function,
but not in patients with severely reduced renal
function [12]. Similar findings have been
reported for other SGLT2 inhibitors in
pharmacokinetic/pharmacodynamic studies
and longer term studies [6].
To our knowledge, however, no studies have
investigated the relationship between reduced
renal function and daily glucose variability in
patients treated with a SGLT2 inhibitor.
Therefore, to investigate the potential impact
of reduced renal function on 24-h glucose
variability in patients treated with an SGLT2
inhibitor, we performed a subanalysis of our
previously reported study in which patients
were treated with luseogliflozin or placebo for
7 days in a crossover manner, with 24-h
continuous glucose monitoring (CGM) starting
on day 7 of treatment [13].
METHODS
Ethics Statement
As previously described [13], the study was
conducted in accordance with the ethical
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standards of the Helsinki Declaration of 1975, as
revised in 2013, the Japanese Pharmaceutical
Affairs Law, Good Clinical Practice, and
institutional and national recommendations
on clinical trials. The study protocol was
approved by the Institutional Review Board of
each institute. Written informed consent was
obtained from all patients before enrolment.
This study was registered with the Japan
Pharmaceutical Information Center (identifier:
JapicCTI-142548).
Study Design
In this double-blind, placebo-controlled,
crossover study, 37 Japanese patients with
T2DM inadequately controlled with diet and
exercise (HbA1c 7.0–10.0%) whose estimated
glomerular filtration rate (eGFR) was C45 mL/
min/1.73 m2 were randomized into two groups
in which patients first received luseogliflozin
then placebo, or vice versa, for 7 days each.
Each treatment period was separated by a
washout period of 7–14 days. Patients were
hospitalized on day 7 and consumed a
standardized meal (536 kcal, with
approximately 20% protein, 25% fat, and 55%
carbohydrate) at breakfast, lunch, and dinner.
Twenty-four-hour CGM was started on day 7.
Because the data for one patient who left a
relatively large amount of the standardized
meal at breakfast and two patients who did
not complete the 24-h CGM were excluded
from this subanalysis, 34 patients were divided
into three groups according to their baseline
eGFR: normal (C90 mL/min/1.73 m2; n = 13),
normal-to-mildly reduced renal function (C75
to \90 mL/min/1.73 m2; n = 12), or
mild-to-moderately reduced renal function
(\75 mL/min/1.73 m2; n = 9). We chose the
cutoff value of 75 mL/min/1.73 m2 because
this represents an intermediate value in stage
2 chronic kidney disease (defined as eGFR of
C60 to \90 mL/min/1.73 m2) and provided
similar numbers of patients in each group. To
evaluate the difference between groups of
patients in the difference between
luseogliflozin and placebo, one-way analysis of
variance (ANOVA) were used to analyze the
normally distributed variables, and
Kruskal–Wallis test were used to analyze the
non-normally distributed variables.
Data Analysis
The primary endpoints of the original study
were indices derived from CGM. Other efficacy
endpoints were pharmacodynamic variables,
including serum insulin concentrations,
plasma glucagon concentrations, and urinary
glucose concentrations (pooled urine and 24-h
urine samples). The following variables were
calculated using the CGM data: 24-h mean
glucose, area under the curve (AUC), peak blood
glucose concentration, time to peak blood
glucose concentration, and blood glucose
concentration in preprandial or fasting
periods. The glucose concentration–time
curves were analyzed for the following periods:
0–24 h, after breakfast (0–5 h), after lunch
(5–11 h), after dinner (11–15 h), and the
sleeping period (15–24 h). Pharmacodynamic
variables included the AUC and the maximum
concentration (Cmax) for serum insulin and
plasma glucagon. Cumulative UGE was also
calculated.
All statistical analyses were performed using
SAS software (version 9.2; SAS Institute Inc.,
Cary, NC, USA). Mixed-effects models were used
to analyze normally distributed variables, after
visual inspection of the histogram for each
variable. The mixed-effects models included
treatment, sequence and period as fixed
effects, and patient as a random effect. The
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least-squares mean differences between
luseogliflozin and placebo with 95%
confidence intervals (95% CI) were estimated
for each variable in the mixed-effects models.
Non-normally distributed variables were
analyzed using Wilcoxon signed-rank test and
the median and the interquartile range of
differences between luseogliflozin and placebo
were calculated.
To evaluate the difference between groups in
the difference between luseogliflozin and
placebo, ANOVA were used to analyze the
normally distributed variables, and
Kruskal–Wallis test were used to analyze the
non-normally distributed variables.
RESULTS
The demographic and baseline characteristics of
the patients of each group are shown in Table 1.
Although glucose-related variables tended to be
lower in the mild–moderate group, there were
no significant differences between groups.
The variations in 24-h glucose
concentrations measured by CGM and the
UGE rates on day 7 of treatment with
luseogliflozin and placebo are shown in Fig. 1.
The 24-h glucose variables derived from CGM
are shown in Table 2 and the pharmacodynamic
variables are shown in Table 3.
Although glucose variability was consistently
lower with luseogliflozin than with placebo in
the normal and normal–mild groups, glucose
variability was not consistently lower with
luseogliflozin than with placebo in the
mild–moderate group, because of the smaller
change in postprandial glucose concentrations
in this group.
The mean 24-h glucose was lower with
luseogliflozin than with placebo in all three
groups. However, the placebo-subtracted
change in the mean 24-h glucose was smaller
in the mild–moderate group than in the normal
and normal–mild groups. The
placebo-subtracted change in mean 24-h
glucose was therefore significantly different
between groups (P = 0.023, ANOVA).
The AUC0–24 h for glycemic variability was
smaller with luseogliflozin than with placebo in
all three groups. However, the
placebo-subtracted change in the AUC0–24 h for
glycemic variability was smaller in the
mild–moderate group than in the normal and
normal–mild groups. The placebo-subtracted
change in the AUC0–24 h for glycemic
variability was significantly different between
groups (P = 0.023, ANOVA). The AUCs for
glycemic variability after each meal (i.e.,
AUC0–5 h, AUC5–11 h, and AUC11–15 h) and
during the sleeping period (AUC15–24 h) were
also smaller with luseogliflozin than with
placebo in all three groups. The
placebo-subtracted AUCs for glycemic
variability were significantly different between
groups at breakfast and lunch (P = 0.006 and
P = 0.026, respectively, ANOVA).
The peak glucose concentrations throughout
the day and after each meal were significantly
lower with luseogliflozin than with placebo in
the normal and normal–mild groups, but not in
the mild–moderate group. The
placebo-subtracted difference in the peak
glucose concentration was significantly
different between groups after breakfast
(P = 0.047, ANOVA), but not at the other
measurement times.
The fasting glucose concentrations (i.e.,
glucose concentration measured before each
meal and in the sleeping period) were
consistently lower with luseogliflozin than
with placebo in all three groups. Furthermore,
the placebo-subtracted changes in the fasting
Adv Ther (2016) 33:460–479 463
glucose concentrations were not significantly
different between groups.
The lowest glucose concentration from 0 to
24 h was lower with luseogliflozin than with
placebo in all groups. The placebo-subtracted
change in the lowest glucose concentration was
not significantly different between groups.
Luseogliflozin significantly increased the
cumulative UGE compared with placebo in all
of the periods in all three groups (all P\0.05).
However, the placebo-subtracted changes in the
cumulative UGE were smaller in the
mild–moderate group than in the normal and
normal–mild groups, and these differences were
statistically significant between groups for all
measurement times except after dinner
(throughout the day: P = 0.007; after breakfast:
P = 0.037; after lunch: P = 0.007; after dinner:
P = 0.198; sleeping period: P = 0.050, ANOVA).
The serum insulin and plasma glucagon
levels on day 7 in each treatment period are
shown in Fig. 2. The serum insulin
concentrations were consistently lower
throughout the day with luseogliflozin than
with placebo. The AUCs for serum insulin after
each meal, during the sleeping period, and from
0 to 24 h were also smaller with luseogliflozin
than with placebo in all three groups. The
plasma glucagon concentrations were higher
throughout the 24-h measurement period with








n 9 12 13
Age (years) 64.0 ± 7.7 62.8 ± 9.3 57.9 ± 7.8 0.194
Body weight (kg) 62.86 ± 13.91 67.93 ± 15.99 65.32 ± 11.88 0.713
BMI (kg/m2) 25.25 ± 4.36 24.73 ± 3.81 24.16 ± 3.13 0.794
Disease duration (years) 6.1 ± 3.4 8.1 ± 4.9 7.2 ± 4.1 0.576
HbA1c (%) 7.43 ± 0.68 7.90 ± 0.77 7.90 ± 0.77 0.290
FPG (mg/dL) 148.8 ± 29.5 165.5 ± 27.4 158.8 ± 20.4 0.344
Glycosylated albumin (%) 21.18 ± 4.92 23.16 ± 3.16 21.08 ± 2.98 0.308
Serum insulin (lU/mL) 8.528 ± 3.284 8.349 ± 5.563 7.779 ± 4.430 0.921
Plasma glucagon (pg/mL) 84.4 ± 12.9 90.8 ± 40.7 82.8 ± 27.7 0.795
eGFR (mL/min/1.73 m2) 66.2 ± 5.5 82.7 ± 3.9 100.5 ± 8.4 \0.001
SBP (mmHg) 120.3 ± 14.7 133.1 ± 13.1 122.4 ± 11.6 0.058
DBP (mmHg) 75.3 ± 11.3 79.8 ± 9.4 74.4 ± 6.3 0.294
Urinary albumin corrected for urinary creatinine (mg/g Cr) 47.79 ± 52.29 30.47 ± 27.16 11.35 ± 9.80 0.040
Data are mean ± standard deviation. The differences between groups were analyzed by one-way ANOVA
Glucose: 1 mg/dL = 0.0556 mmol/L
Insulin: 1 lU/mL = 6.945 pmol/L
Glucagon: 1 pg/mL = 1 ng/L
BMI body mass index, DBP diastolic blood pressure, eGFR estimated glomerular ﬁltration rate, FPG fasting plasma glucose,
HbA1c hemoglobin A1c, SBP systolic blood pressure
a Between-group difference
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luseogliflozin than with placebo, and the AUCs
for plasma glucagon were higher with
luseogliflozin than with placebo in almost all
period in all groups. The placebo-subtracted
differences in serum insulin- and plasma
glucose-related variables were not significantly
different between groups.
DISCUSSION
In this post hoc subanalysis, we investigated the
impact of renal function decline on the
glucose-lowering effects of luseogliflozin,
including 24-h glucose variability, as well as
pharmacodynamic variables. For the purpose of
this subanalysis, we divided the patients into
three groups based on their baseline eGFR:
normal renal function, normal-to-mildly
reduced renal function, and
mild-to-moderately reduced renal function.
There were no significant differences in the
demographic and baseline characteristics of
between groups of patients, with the
exceptions of eGFR and urinary albumin
corrected for urinary creatinine.
We noted some differences in the variables
derived from 24-h CGM among the three
groups of patients. Although luseogliflozin
decreased the fasting glucose concentrations
(i.e., before each meal and in the sleeping
period) in all three groups, it did not
significantly reduce the postprandial glucose
concentrations relative to placebo in the
mild–moderate group. Furthermore, consistent
with our original findings [13], luseogliflozin
significantly increased the cumulative UGE
Fig. 1 a Twenty-four-hour glucose concentrations
measured by continuous glucose monitoring (1 mg/dL =
0.0556 mmol/L). Values are presented as the mean (error
bars were omitted for clarity). b Urinary glucose excretion
rate. Values are as the mean ? standard deviation.
*P\0.05 for luseogliﬂozin vs. placebo
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compared with placebo in each of the three
groups. However, the placebo-subtracted
change in UGE was slightly smaller in the
mild–moderate group than in the other two
groups. This result is consistent with those of a
previous study showing that UGE is attenuated
in patients with renal impairment, owing to a
reduction in glucose filtered through the
glomeruli [12]. It seems feasible that
luseogliflozin could not suppress the sharp
glucose fluctuations in the postprandial
periods in the mild–moderate group owing to
the reduced amount of glucose that can be
filtered through the glomerulus in individuals
with reduced renal function. In normal
conditions, the kidney can filter about 180 g
of glucose per day, and this amount is likely to
be reduced in individuals with reduced renal
function. In fasting conditions (i.e., before each
meal and overnight), the amount of glucose
filtered through the kidney is likely to be
relatively stable and manageable in all
patients, albeit at a lower level in patients with
reduced renal function than in patients with
normal renal function. However, in patients
with reduced renal function, the kidney is less
able to respond to sudden increases in glucose
concentrations, especially after a meal, limiting
the impact of SGLT2 inhibitors on UGE.
Nevertheless, the placebo-subtracted change in
fasting glucose was smaller in the
mild–moderate group than in the other
Fig. 2 a Twenty-four-hour serum insulin levels after 7 days
of once-daily administration of 2.5 mg luseogliﬂozin or
placebo. Values are means ? standard deviation.
b Twenty-four-hour plasma glucagon levels after 7 days of
once-daily administration of 2.5 mg luseogliﬂozin or
placebo. Values are mean ? standard deviation
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groups, probably because of the lower baseline
value in this group, being closer to the renal
threshold for glucose reabsorption in the kidney
[14]. The fasting glucose concentrations with
luseogliflozin were similar between groups,
which might be related to the renal threshold
for glucose and the low risk of hypoglycemia in
patients treated with SGLT2 inhibitors.
Luseogliflozin also decreased insulin
concentrations and decreased the AUC of
insulin in all of the groups. It is possible that
these changes were driven by the reductions in
circulating glucose concentrations. These
findings suggest that luseogliflozin may reduce
insulin secretion in patients with normal renal
function or mildly reduced renal function. It is
also notable that luseogliflozin increased
plasma glucagon concentrations throughout
the day in all three groups. This effect of
luseogliflozin may be due to enhanced
gluconeogenesis to prevent excessive
reductions in circulating glucose, especially in
fasting conditions.
Several pharmacokinetic/pharmacodynamic
studies have demonstrated that the effects of
SGLT2 inhibitors on UGE and plasma glucose
concentrations are attenuated by reduced renal
function, especially severely reduced renal
function or chronic kidney disease [6, 15–18],
consistent with our findings using 24-h CGM.
Our results provide further insight into the
impact of reduced renal function on the
glucose-lowering effects of SGLT2 inhibitors,
and that co-administration of a SGLT2 inhibitor
with another antidiabetic drug, which improves
postprandial glucose, might be useful for the
patients with reduced renal function if
improvements in glucose concentrations are
not observed with monotherapy. It is
particularly notable that the effects of
luseogliflozin on postprandial glucose
concentrations were attenuated in individuals
with mild–moderate reductions in renal
function relative to the other groups, but the
reduction in fasting blood glucose was
essentially unaffected by reduced renal
function. Therefore, the reduced efficacy of
SGLT2 inhibitors on overall glycemic control
(i.e., HbA1c) is likely to be driven by the smaller
reductions in postprandial glucose fluctuations,
a major contributor to overall glycemic
variability.
It is also important to consider that reduced
renal function may increase systemic exposure
to luseogliflozin, as has been demonstrated for
dapagliflozin [19]. An increase in exposure may
increase the risk of unwanted side effects, and
dose adjustments may be necessary in
individuals with moderate-to-severely reduced
renal function, although this possibility must
be evaluated in longer term studies of patients
with moderate-to-severely reduced renal
function.
Some limitations of this study warrant
mention. In particular, because these
subanalyses were conducted in a post hoc
exploratory manner, the number of patients
differed between groups. Accordingly, it will be
necessary to conduct prospective studies of
larger numbers of patients to examine the
impact of reduced renal function on the
glucose-lowering effects of luseogliflozin and
the implications, if any, on the clinical use of
luseogliflozin. In addition, we did not enroll
patients with moderate-to-severely reduced
renal function. Considering that the changes
in glucose-related variables were lower in the
mild–moderate group than in the normal and
normal–moderate groups, it is possible that
moderate-to-severely reduced renal function
will attenuate the clinical efficacy of
luseogliflozin by reducing UGE and affecting
glucose variability. Indeed, in a 24-week
randomized, placebo-controlled trial of
476 Adv Ther (2016) 33:460–479
Japanese patients with T2DM, ipragliflozin
significantly improved glycemic control in
patients with mildly reduced renal function
but not in patients with moderately reduced
renal function [20]. However, it was reported
that canagliflozin significantly reduced HbA1c,
body weight, and blood pressure among
patients with stage 3 chronic kidney disease
(defined as eGFR C30 to\60 mL/min/1.73 m2)
[21]. Therefore, it will be necessary to evaluate
the efficacy of luseogliflozin in patients with
moderate-to-severely reduced renal function
and in patients with mildly reduced renal
function. Finally, patients were only
administered luseogliflozin and placebo for
7 days each. Therefore, longer studies are
required to examine the clinical relevance of
the present results in terms of the changes in
HbA1c.
CONCLUSIONS
The results of this post hoc subanalysis indicate
that the effects of luseogliflozin on lowering
postprandial glucose are attenuated in patients
with mild-to-moderately reduced renal function
(eGFR\75 mL/min/1.73 m2). Nevertheless, the
improvements in fasting glucose concentrations
measured before each meal and during the
sleeping period and the reductions in insulin
concentrations in patients with
mild-to-moderately reduced renal function
were similar to those in patients with normal
renal function or patients with
normal-to-mildly reduced renal function.
These findings suggest that luseogliflozin
improves fasting glucose concentrations, at
least, without increasing the burden on
pancreatic b-cells in patients with
mild-to-moderately reduced renal function.
Furthermore, the results suggest that
luseogliflozin can be used in combination with
other oral antidiabetic agents, which improve
postprandial glucose, in patients with reduced
renal function.
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